Biogen Inc., a frontrunner in biotechnology, made a significant stride on Wednesday, May 22nd, 2024, by announcing its agreement to acquire Human Immunology Biosciences (HIB) for a total consideration of up to $1.8 billion. This strategic move not only bolsters Biogen’s presence in the field of immune disease treatments but also underscores its commitment to advancing transformative therapies. The deal structure involves an upfront payment of $1.15 billion to HIB, a privately held company. Additionally, Biogen will pay up to
